On December 15th, the "Fourth China Biopharmaceutical Industry Chain Innovation Awards Ceremony" was held in Hangzhou. PharmaBlock Sciences (Nanjing), Inc. (Stock code: 300725. SZSE), received the "Annual Influential CDMO Enterprise" and the "Annual Influential CRO Enterprise" awards at the 2023 Innovation Billboard.

 Annual Influential CDMO Enterprise

PharmaBlock leverages its unique core resource of novel building blocks and chemistry excellence to empower its CRDMO services, which support customers  throughout the drug discovery, development and commercial stages with faster development speed, sustainable supply, and more effective cost control. Furthermore, PharmaBlock has been actively building up cutting-edge technology platform featuring flow chemistry, micropacked bed technology, and catalysis, making drug development and manufacturing more efficient and environmentally friendly.

The company's dual award win highlights its robust capabilities in CRDMO service. Going forward. PharmaBlock will maintain its focus on the development of an integrated CRDMO service platform. Taking full advantage of chemistry and low-carbon technology innovation, the company aims to inspire drug discovery, accelerate drug development, and offer greener and more sustainable solutions for the global pharmaceutical industry, thereby creating value for human health and social development.